For example, engagers targeting NK cells to CD30+ lymphomas, CD33+ myelodysplastic syndrome, CD133+ colon cancer, CLEC12A+ and CD33+ AML are all in clinical development. This evidence concerns the gene CD33 and myelodysplastic syndrome.